- Home
- XAIR vs BNR Comparison
XAIR vs BNR Comparison
Compare XAIR & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- BNR
- Stock Information
- Founded
- XAIR 2011
- BNR 2014
- Country
- XAIR United States
- BNR China
- Employees
- XAIR N/A
- BNR N/A
- Industry
- XAIR Medical/Dental Instruments
- BNR Medical Specialities
- Sector
- XAIR Health Care
- BNR Health Care
- Exchange
- XAIR Nasdaq
- BNR Nasdaq
- Market Cap
- XAIR 34.7M
- BNR 28.6M
- IPO Year
- XAIR N/A
- BNR 2020
- Fundamental
- Price
- XAIR $0.50
- BNR $3.77
- Analyst Decision
- XAIR Strong Buy
- BNR
- Analyst Count
- XAIR 4
- BNR 0
- Target Price
- XAIR $3.67
- BNR N/A
- AVG Volume (30 Days)
- XAIR 636.5K
- BNR 21.0K
- Earning Date
- XAIR 11-11-2024
- BNR 11-29-2024
- Dividend Yield
- XAIR N/A
- BNR N/A
- EPS Growth
- XAIR N/A
- BNR N/A
- EPS
- XAIR N/A
- BNR N/A
- Revenue
- XAIR $2,342,000.00
- BNR $70,154,674.00
- Revenue This Year
- XAIR $640.47
- BNR $52.90
- Revenue Next Year
- XAIR $286.81
- BNR $48.35
- P/E Ratio
- XAIR N/A
- BNR N/A
- Revenue Growth
- XAIR 685.91
- BNR N/A
- 52 Week Low
- XAIR $0.30
- BNR $2.62
- 52 Week High
- XAIR $2.36
- BNR $9.99
- Technical
- Relative Strength Index (RSI)
- XAIR 56.04
- BNR 61.38
- Support Level
- XAIR $0.42
- BNR $2.65
- Resistance Level
- XAIR $0.56
- BNR $3.89
- Average True Range (ATR)
- XAIR 0.07
- BNR 0.30
- MACD
- XAIR 0.00
- BNR 0.12
- Stochastic Oscillator
- XAIR 47.32
- BNR 90.32
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.